JAB-8263 not checked

Jacobio Pharmaceuticals Co., Ltd.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
2 active
3 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Rheumatoid Arthritis (RA), NSCLC, SCLC, CRPC, ESCC, Ovarian Carcinoma, AML, MF and 1 more
Main trialPhase 2
“This study is an open-label, multi-center Phase IIa study. The study is divided into two phases. The first phase is a safety exploration phase. Participants with active rheumatoid arthritis were enrolled and treated with JAB-8263 alone for 4 weeks. The purpose is to evaluate the safety, PK/PD characteristics and preliminary effectiveness of JAB-8263 in participants with active RA.”In the company’s words, NCT07684157 on ClinicalTrials.gov

Other drugs for Rheumatoid Arthritis (RA)

All 80 drugs for Rheumatoid Arthritis (RA)

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 2Recruiting 30 Jun 2027 A Phase IIa Study of JAB-8263 in Patients With Active Rheumatoid Arthritis
Phase 1/2Recruiting Jan 2028 A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors
Phase 1Completed 31 Oct 2024 A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026

Follow JAB-8263

Following is part of Solo: you see every change to JAB-8263 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in